Discovery of Vascular Targets

A major requirement for the development of antibody-based therapeutics is the identification of antigens specifically expressed at sites of disease and accessible from the bloodstream. Philochem scientists in collaboration with ETH Zurich have pioneered the use of chemical proteomics strategies to enrich and quantify proteins on the cell surface or in the extracellular space, which can be drugged by therapeutic antibodies. The extensive publication track record of Philochem scientists in the field of chemical proteomics confirms our success in biomarker identification for various diseases including cancer.